DTaP/IPV/Hib/HepB (6 in 1) vaccine - 6 in 1 vaccine information for health professionals
Some of the links included in this information lead to content created by other organisations and may not be available in Welsh.
Background
Diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, Hib (Haemophilus influenzae type b) and hepatitis B are notifiable diseases.
The 6-in-1 vaccine
The 6-in-1 vaccine helps protect against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, Hib (Haemophilus influenzae type b) and hepatitis B, and was introduced for all UK babies born on, or after 1st August 2017.
The first three doses of Hib-containing vaccine are administered at 8, 12, and 16 weeks with the 6-in-1 (DTaP/IPV/Hib/HepB) vaccine. From 1 January 2026 an additional dose of the 6-in-1 vaccine is given at 18 months of age.
Menitorix© (Hib/MenC) was discontinued on 30 June 2025. The 18‑month dose replaces the Hib component previously provided at 12 months via Menitorix©.
Where can I find more information about schedule changes to the routine childhood vaccination programmes?
You can find more information about schedule changes to the routine childhood vaccination programmes on our website.
About the vaccine
The 6-in-1 vaccine is marketed for use in the UK under the brand names Infarix hexa® and Vaxelis®.
Infanrix hexa® is an inactivated vaccine in a powder and suspension for reconstitution before injection. Vaxelis® is an inactivated injectable vaccine in a pre-filled syringe presentation.
Guidance on the treatment of tetanus cases and management of tetanus prone wounds can be is available at:
- Tetanus: advice for health professionals (external site)
- Tetanus: the green book, chapter 30 (external site)
Summary of product characteristics
More information about the vaccine can be found in the Green Book chapters for each disease. See Clinical resources and information section.
Guidance in the Green Book supersedes the Summary of product characteristics (SmPC).
Reporting side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. You should report suspected adverse reactions of vaccines and medicines online at Yellow Card (external site), by downloading the Yellow Card app, or by calling 0800 731 6789 (Monday to Friday, 9am to 5pm).
Guidance
Vaccination programme recommendations from the Joint Committee on Vaccination and Immunisation (JCVI) and Welsh Government policy can be found at the links below.
Joint Committee on Vaccination and Immunisation (external site) - read JCVI publications and statements; search e.g. polio.
Guidance on changes to the childhood immunisation schedule in Wales
Changes to the childhood immunisation schedule: JCVI statement (external site)
The Complete Routine Immunisation Schedule for Wales is available on our website and includes information about routine and non-routine vaccinations.
Policy and guidance can also be found on the Public Health Wales Policy, letters and Welsh Government (external site) SharePoint page (access for NHS healthcare staff)
- Hexavalent vaccine for baby immunisation schedule (WHC/2017/039) (external site)
- Changes to routine childhood and selective neonatal hepatitis B vaccinations (WHC/2025/019) (external site)
- Hepatitis B (HepB) – Information for health professionals
- Attaining the WHO targets for eliminating hepatitis B and C (WHC/2017/048) (external site)
Guidance for health professionals on the treatment and reduction of cases of hepatitis. Eliminating hepatitis (B and C) as a public health threat: actions for 2022 to 2023 and 2023 to 2024 (WHC/2023/001) (external site)
Letter to health boards on the actions they need to take to make progress on hepatitis B and C elimination. Written Statement: Eliminating hepatitis B and C as a public health threat (3 February 2023) (external site)
Training resources and events
Online courses and training materials about a number of vaccines and diseases can be accessed via the E-learning page.
Further training information and resources are provided on the Training Resources and Events page.
Clinical resources and information
- Diphtheria – the green book, chapter 15 (external site)
- Tetanus – the green book, chapter 30 (external site)
- Pertussis - the green book, chapter 24 (external site)
- Polio – the green book, chapter 26 (external site)
- Haemophilus influenzae type b (Hib) - the green book, chapter 16 (external site)
- Hepatitis B - the green book, chapter 18 (external site)
- Hexavalent combination vaccine: programme guidance (external site) (Applies to England)
- Tetanus: advice for health professionals (external site)
- Vaccination of individuals with uncertain or incomplete immunisation status (external site)
Patient group directions (PGDs) and protocols
PGD templates for vaccines can be found on the Welsh Medicines Advice Service (external site) page.
Further clinical resources and information
More information
Data and surveillance
Vaccination surveillance information can be found on the pages below:
- Immunisation surveillance
- COVER – National childhood immunisation uptake data
- Diphtheria disease: guidance, data and analysis (external site)
- Tetanus: guidance, data and analysis (external site)
- Pertussis (whooping cough) surveillance and epidemiology
- Pertussis: guidance, data and analysis (external site)
- Polio: guidance, data and analysis (external site)
- Haemophilus influenzae: guidance, data and analysis (external site)
- Hepatitis B: guidance, data and analysis (external site)
Page last reviewed: 6th July 2026